AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a report released on Wednesday.
Other analysts have also issued research reports about the company. Berenberg Bank lifted their target price on AstraZeneca plc from GBX 4,950 ($61.41) to GBX 5,400 ($66.99) and gave the stock a “buy” rating in a report on Tuesday, July 12th. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, July 27th. Bryan, Garnier & Co restated a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, July 28th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,800 ($71.95) price target on shares of AstraZeneca plc in a research note on Friday, July 29th. Finally, BNP Paribas set a GBX 5,300 ($65.75) price target on AstraZeneca plc and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 4,958.40 ($61.51).
Shares of AstraZeneca plc (LON:AZN) traded down 1.23% during trading on Wednesday, reaching GBX 4248.50. The company’s stock had a trading volume of 1,789,464 shares. The company’s market cap is GBX 53.74 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The company has a 50 day moving average of GBX 4,592.74 and a 200 day moving average of GBX 4,592.37.